Document is current
Any future updates will be listed below
-
Authors
Varnier, Romain
Puszkiel, Alicja
Tod, Michel
Calattini, Sara
Payen, Lea
Lopez, Jonathan
Guitton, Jérome
Schwiertz, Vérane
Fontaine, Juliette
Peron, Julien
Maillet, Denis
Tartas, Sophie
Bonnin, Nathalie
Colomban, Olivier
Augu-Denechere, Diane
Freyer, Gilles
You, Benoit https://orcid.org/0000-0002-3177-8857
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01932177 at ClinicalTrials.govDocuments that mention this clinical trial
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors
https://doi.org/10.1007/s00280-023-04508-9
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial
https://doi.org/10.1007/s00280-023-04520-z
-
Funding
Funding for this research was provided by:
Hospices Civils de Lyon (bourse Actions Incitatives)
Ligue Contre le Cancer
Association de Recherche contre le Cancer
Novartis
Institut National Du Cancer
- License Information
-
More Information
Article History
Received: 1 April 2022
Accepted: 27 January 2023
First Online: 25 February 2023
Declarations
:
: The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
: The authors state that they have obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.
